A detailed history of Dimensional Fund Advisors LP transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 40,098 shares of LYEL stock, worth $60,547. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,098
Previous 13,463 197.84%
Holding current value
$60,547
Previous $30,000 93.33%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.3 - $3.01 $34,625 - $80,171
26,635 Added 197.84%
40,098 $58,000
Q2 2023

Aug 09, 2023

SELL
$1.89 - $3.86 $55,342 - $113,028
-29,282 Reduced 68.5%
13,463 $42,000
Q1 2023

May 12, 2023

SELL
$1.97 - $3.58 $180,942 - $328,819
-91,849 Reduced 68.24%
42,745 $100,000
Q4 2022

Feb 09, 2023

BUY
$2.78 - $8.09 $42,592 - $123,946
15,321 Added 12.85%
134,594 $467,000
Q3 2022

Nov 10, 2022

BUY
$5.54 - $8.27 $660,772 - $986,387
119,273 New
119,273 $874,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $374M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.